AbbVie

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

AbbVie (ABBV) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $2.21 per share. This compares to earnings of $2 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 2.26%. A quarter ago, it was expected that this drugmaker would post earnings of $2.06 per share when it actually produced earnings of $2.14, delivering a surprise of 3.88%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.26 billion for the quarter ended June 2019, surpassing the Zacks Consensus Estimate by 1.89%.


...

https://finance.yahoo.com/news/abbvie-ab...01529.html

AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates

AbbVie (ABBV) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.20 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 0.45%. A quarter ago, it was expected that this drugmaker would post earnings of $2.29 per share when it actually produced earnings of $2.33, delivering a surprise of 1.75%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.70 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.03%. This compares to year-ago revenues of $8.31 billion.


...

https://finance.yahoo.com/news/abbvie-ab...02013.html

AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates

AbbVie (ABBV) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.20 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 0.45%. A quarter ago, it was expected that this drugmaker would post earnings of $2.29 per share when it actually produced earnings of $2.33, delivering a surprise of 1.75%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.70 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.03%. This compares to year-ago revenues of $8.31 billion.


...

https://finance.yahoo.com/news/abbvie-ab...02013.html

Das tönt grundsätzlich positiv, aber erklärt das den gestrigen Kursanstieg von 6%?

AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates

AbbVie Inc. ABBV reported earnings of $2.42 per share in the first quarter, comfortably beating the Zacks Consensus Estimate of $2.27 and came ahead of the guided range of $2.28-$2.30. Earnings rose 16.3% year over year.

Meanwhile, the company’s revenues of $8.62 billion beat the Zacks Consensus Estimate of $8.44 billion. Meanwhile, the top line improved 10.1% year over year.


...

https://finance.yahoo.com/news/abbvies-a...02542.html

AbbVie shares rises on strong Q2, though cosmetic Botox sales tumbled 43%

...

The company had a loss of $739 million, or 46 cents per share, in the second quarter of 2020. It had reported a gain of $807 million, or 49 cents a share, in the same quarter in 2019. Adjusted earnings per share were $2.34, ahead of the FactSet consensus of $2.20. Sales increased to $10.4 billion in the quarter compared with $8.2 billion in the period a year ago. The FactSet consensus for revenue for the quarter was $9.9 billion.

...

https://www.marketwatch.com/story/abbvie...latestnews

ABBVIE erhöht die Dividende um satte 10,2% !!!

https://seekingalpha.com/news/3629010-ab...ividend-10

AbbVie EPS beats by $0.06, beats on revenue



bbVie (NYSE:ABBV): Q3 Non-GAAP EPS of $2.83 beats by $0.06; GAAP EPS of $1.29 misses by $0.13.

Revenue of $12.9B (+52.1% Y/Y) beats by $190M.




https://seekingalpha.com/news/3629011-ab...on-revenue

... dass die Überrenditen wahrscheinlich 10 Jahre lang anhalten werden, aber wir können uns bei unserem 20-Jahres-Ausblick, der für ein Wide Moat-Rating erforderlich wäre, nicht so sicher sein. Wir modellieren zwar einen Umsatzrückgang bei Humira in den USA im Jahr 2023, aber der Rückgang wird aufgrund der Komplexität bei der Entwicklung und Vermarktung eines Biosimilars (generisches Biologikum) wahrscheinlich langsamer verlaufen als bei einem typischen Markenmedikament mit kleinen Molekülen, das einer verschärften Konkurrenz durch Generika ausgesetzt ist.
Nichtsdestoweniger erwirtschaftet AbbVie enorme Cashflows aus seinem aktuellen Produktportfolio, um die laufende Entdeckung und Entwicklung der nächsten Generation von Medikamenten zu finanzieren. Diese Cashflows schaffen einen Größenvorteil, der es AbbVie ermöglicht, ...

https://www.morningstar.de/de/news/20805...bbvie.aspx

Moin zusammen,

SSD lässt Abbvie bezüglich der Dividendensicherheit weiterhin bei 50 - also Boarderline-Safe stehen.

Hat sich jemand in lezter Zeit aktuell mit der Produktpipeline von denen beschäftigt ?
Das Portfolio von Allergan ist ja bereits voll integriert, habe nicht viel gutes bzw. vielversprechendes
im letzten Jahr zu AbbVie gelesen was neue Mittel gegen Krebs etc. anbetrifft ?

Der Cashflow ist ja in meinen Augen noch absolut ok, auch wenn die Übernahme von Allergan kein Schnapper
war. Aber das hat ja nichts zu sagen, in der  heutigen Zeit sind die Kosten für Übernahmen nicht mehr zwingend
mit dem vergleichbar, was man vor 5-10 Jahren noch angesetzt hat.

Jemand neue Ideen, Ansätze - oder was interessantes was er zur weiteren Entwicklung erhofft ?

Weiß jetzt nur von einer größeren Konferenz am 26.2. (?)

Hatte mir das für Monatsanfang auf WV gelegt








Je nach Zählweise auf Platz 2 bis 6 innert Branche
Würde sie noch nicht abschreiben